|Bid||39.49 x 100|
|Ask||39.61 x 100|
|Day's range||38.64 - 39.46|
|52-week range||33.60 - 50.40|
|PE ratio (TTM)||39.15|
|Earnings date||9 Aug 2017|
|Dividend & yield||0.00 (0.00%)|
|1y target est||48.74|
First Generic Prequalification for Sofosbuvir Tablets HERTFORDSHIRE, England and PITTSBURGH , July 26, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL), a leading global pharmaceutical company, today ...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Mylan NV Here are 5 ETFs with the largest exposure to MYL-US. Comparing the performance and risk of Mylan NV with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
Sarepta Therapeutics, Inovio Pharmaceuticals and Mylan were among the biotech movers in premarket trading on July 20.